| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 05/08/2002 | CN1347734A Method for treating thrombosis diseases |
| 05/07/2002 | US6384259 Heat resistant, sterile dosage suitable for reconstitution with a vehicle into an injectible, particle-free product for parenteral administration |
| 05/07/2002 | US6384188 Lipopolysaccharide-binding and neutralizing peptides |
| 05/07/2002 | US6384076 Inhibition or erythrocyte sickling by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester |
| 05/07/2002 | US6384069 Brain disorders chronic pain, hypoglycemia, hypoxia, trauma, alzheimer's disease, aids-associated dementia, amyotrophic lateral sclerosis, parkinson's disease, and chronic alcoholism, comprising administering to a patient in need a |
| 05/07/2002 | US6384028 Treatment of cardiovascular disorders, anticoagulants and valve replacement |
| 05/07/2002 | US6383785 Self-enhancing, pharmacologically controllable expression systems |
| 05/07/2002 | US6383780 2786, a novel human aminopeptidase |
| 05/07/2002 | US6383528 Antithrombotic preparation to suppress neutropenia, agranulocytosis, ischemia, and other side effects from the use of ticlopidine alone; |
| 05/07/2002 | CA2348845A1 Adenosine as antithrombotic |
| 05/07/2002 | CA1341357C Platelet-specific chimeric immunoglobulin |
| 05/05/2002 | WO2002042270A1 Substituted benzene derivatives or salts thereof |
| 05/02/2002 | WO2002034786A1 Method of eliminating human serum albumin polymers |
| 05/02/2002 | WO2002034783A2 Transmembrane proteins |
| 05/02/2002 | WO2002034779A1 Identification and modification of immunodominant epitopes in polypeptides |
| 05/02/2002 | WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034705A2 C-nitroso compounds and use thereof |
| 05/02/2002 | WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | WO2002034296A1 A novel gene therapy agent for haemophilia b and its preparation method |
| 05/02/2002 | WO2002034262A1 Combination of catechin and quercetin for pharmaceutical or dietary use |
| 05/02/2002 | WO2002034259A1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 05/02/2002 | WO2002034202A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | WO2002011710A3 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 05/02/2002 | WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 05/02/2002 | WO2001091803A3 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 05/02/2002 | WO2001090074A3 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001064642A3 Benzamides and related inhibitors of factor xa |
| 05/02/2002 | WO2001061009A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001054686A3 L-arginine in combination with other compounds for treating cardiovascular diseases |
| 05/02/2002 | WO2001034767A3 22 human secreted proteins |
| 05/02/2002 | WO2001018172A3 Fibroblast growth factor-like polypeptides |
| 05/02/2002 | WO2001018031A3 Peptides and pharmaceutical compositions comprising same |
| 05/02/2002 | WO2001009121A3 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 05/02/2002 | WO2000075365A9 COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION |
| 05/02/2002 | US20020052417 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| 05/02/2002 | US20020052398 Pharmaceutical composition of 6-amino EM-12 |
| 05/02/2002 | US20020052397 Treatment of diseases characterized by excess Th2 cytokines and/ or an excess IgE production. |
| 05/02/2002 | US20020052381 Method of using diketopiperazines and composition containing them |
| 05/02/2002 | US20020052368 Oxindole inhibitors of factor Xa |
| 05/02/2002 | US20020052357 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 05/02/2002 | US20020052355 Inhibition of serotonin reuptake; especially 2-(azabicycloalkyl)alkylenyl)isoquinolin-3-one compounds |
| 05/02/2002 | US20020052343 Salicylamides as serine protease inhibitors |
| 05/02/2002 | US20020052337 Composition and method for inhibiting platelet aggregation |
| 05/02/2002 | US20020052326 Treating diabetes and related diseases in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. |
| 05/02/2002 | US20020052317 Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
| 05/02/2002 | US20020051984 Nucleotide sequences coding cell proliferation protein; for use in the treatment of cancer, wounds, inflammation, arthritis, psoraisis, vision and cell proliferation defects |
| 05/02/2002 | EP1201248A2 Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease |
| 05/02/2002 | EP1201246A2 Use of thrombopoietin as a medicament for the therapy and prevention of thrombocytopenia |
| 05/02/2002 | EP1201136A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/02/2002 | EP1200837A1 A method for predicting the presence of haemostatic dysfunction in a patient sample |
| 05/02/2002 | EP1200596A2 Human synthetases |
| 05/02/2002 | EP1200595A2 Myxoma virus genes for immune modulation |
| 05/02/2002 | EP1200587A2 Receptors and associated proteins |
| 05/02/2002 | EP1200582A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 05/02/2002 | EP1200562A2 Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders |
| 05/02/2002 | EP1200555A1 Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell |
| 05/02/2002 | EP1200437A1 Method for producing by stereospecific hydration tetrahydropterins and optically pure derivatives, in particular tetrahydrofolic acid and its optically pure derivatives |
| 05/02/2002 | EP1200432A1 Amido spiropiperidines promote the release of growth hormone |
| 05/02/2002 | EP1200422A2 Pyrazole compositions useful as inhibitors of erk |
| 05/02/2002 | EP1200415A1 Diamino-1,2,4-triazole-carboxylic acid derivatives as gsk-3 inhibitors |
| 05/02/2002 | EP1200405A1 Benzenamine derivatives as anti-coagulants |
| 05/02/2002 | EP1200400A1 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
| 05/02/2002 | EP1200385A1 Crystals of the sodium salt of pravastatin |
| 05/02/2002 | EP1200151A1 Drug delivery device for insertion into the vagina, rectum or nasal cavity |
| 05/02/2002 | EP1200137A1 Agent for occluding blood vessels |
| 05/02/2002 | EP1200124A1 Immunoglobulin fusion proteins |
| 05/02/2002 | EP1200118A1 A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug |
| 05/02/2002 | EP1200115A2 Multi-dose erythropoietin formulations |
| 05/02/2002 | EP1200105A1 Modified factor viii |
| 05/02/2002 | EP1200085A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 05/02/2002 | EP0840740B1 New inhibitors of platelet aggregation |
| 05/02/2002 | DE10050935A1 Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen Using CD28 monoclonal antibody specific for the stimulation of blood cells, which carry no CD28 |
| 05/02/2002 | CA2678256A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2427085A1 Transmembrane proteins |
| 05/02/2002 | CA2427005A1 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | CA2426773A1 Beta-substituted beta-aminoethyl phosphonates |
| 05/02/2002 | CA2425288A1 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | CA2422953A1 Identification and modification of immunodominant epitopes in polypeptides |
| 05/02/2002 | CA2422787A1 C-nitroso compounds and use thereof |
| 05/02/2002 | CA2421885A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/01/2002 | CN1347415A Tricyclic pyridine N-oxides vasopressin agonists |
| 05/01/2002 | CN1347326A BAFF, inhibitors thereof and their use in modulation of B-cell response |
| 05/01/2002 | CN1347325A Novel amide derivs. as growth hormone secretagogues |
| 05/01/2002 | CN1346648A Diemailing injection and its preparing process |
| 05/01/2002 | CN1346640A Freeze dried leech capsule |
| 05/01/2002 | CN1083834C Nipecotic acid derivs. as antithrombic compounds |
| 05/01/2002 | CN1083718C Hemostatic oral liquor |
| 04/30/2002 | US6380430 Biphenyl derivatives |
| 04/30/2002 | US6380374 Isolated nucleic acid; culture product |
| 04/30/2002 | US6380260 Administering 1-(1-(4-chlorophenyl) cyclobutyl)-3-methylbutyl amine derivative to human for decreasing platelet adhesiveness |
| 04/30/2002 | US6380258 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 04/30/2002 | US6380251 Therapy of ocular hypertension which comprises administering cyclopentane heptan(ene)oic acid or its 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives |
| 04/30/2002 | US6380250 Therapy of ocular hypertension which comprises administering cyclopentane heptan(ene)oic acid or its 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives |
| 04/30/2002 | US6380244 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 04/30/2002 | US6380238 Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands |
| 04/30/2002 | US6380221 Ortho-anthranilamide derivatives as anti-coagulants |
| 04/30/2002 | US6380218 For therapy of respiratory, allergic, and inflammatory disorders comprising asthma, chronic obstructive pulmonary disease, acute respiratory disease syndrome, pulmonary hypersensitivity, and allergic rhinitis in a mammal |
| 04/30/2002 | US6380215 For prevention and/or treatment of diseases caused by thrombus formation such as arterial thrombosis, arterial sclerosis, ischemic heart diseases |